The latter event on one hand promotes immune suppression of anti-tumor CD8+ T cell responses and engages the PD−1 receptor on cytotoxic CD8+ T cells, effectively suppressing the anti-tumor immune response [82,83,84] and facilitating immune evasion and tumor growth, and on the other hand is associated with a better response to the anti-PD-L1 therapy [18,85,86,87]. This evidence concerns the gene CD8A and neoplasm.